Jim Wooldridge

Jim is the Acting Chief Medical Officer at Gilboa Therapeutics and brings more than 20 years of drug development experience in academia and industry. He received a medical degree from Tulane University and completed post-graduate training in Internal Medicine and Medical Oncology at the University of Iowa. He began his career as a clinical and translational cancer researcher in academia, followed by more than a decade at Eli Lilly and Company, where he developed and oversaw several early-phase cancer clinical research programs, led Oncology US Medical Affairs, and served as the Chief Scientific Officer for Immuno-oncology Clinical Development. He then served as Chief Medical Officer for Aeglea BioTherapeutics, where he oversaw cancer and rare disease clinical development of pegzilarginase, which received Breakthrough Designation for Arginase 1 Deficiency. He most recently served as Chief Medical Officer for Checkmate Pharmaceuticals, where he assisted in taking the company public and led the development of vidutolimod in registration-directed and expanded proof-of-concept studies until the company was acquired in May 2022.